COMP Compass, Inc.

The Russell 2000 (^RUT) is packed with potential breakout stocks, thanks to its focus on smaller companies with high growth potential. However, smaller size also means these businesses often lack the resilience and financial flexibility of large-cap firms, making careful selection crucial.

Coldwell Banker Realty CEO Kamini Rangappan Lane said rising mortgage rates are affecting housing activity as consumers respond to higher borrowing costs, inflation, and economic uncertainty. In an interview with CNBC’s "Squawk on the Street" on Thursday, Lane said mortgage...

Compass (COMP) continues to draw attention after recent trading that left the stock down over the past month and past 3 months, even as annual revenue and net income figures remain positive in absolute terms. Across 2024, Compass has swung from a strong 1 year total shareholder return of about 18% to a much weaker 30 day share price return, down roughly 14%. The recent pullback from around US$9.38 signals fading short term momentum despite earlier gains for longer term holders. Scan beyond...

The battle between real estate listing giants Compass and Zillow heated up on two fronts recently. First, a federal judge in Chicago earlier this month sent part of Zillow’s antitrust case against Compass and Illinois multi-listing provider Midwest Real Estate Data (MRED) to arbitration. Zillow alleges that MRED and Compass teamed up to force Zillow—by cutting Zillow’s access to listings—to abandon its standards.

In a letter obtained by Inman, Compass raised concerns about MLS data supplied to vendors including Courted, BrokerMetrics and Brokerkit.

Some of the biggest news and trends captured in PharmaVoice’s newsletter this week. Sign up here to receive the newsletter daily. Another big AI haul Investors are still lining up to back AI drug developers before their candidates reach human trials. Basecamp Research...

Several analysts slashed their price targets on Compass Therapeutics after the FDA requested an additional trial for its cancer drug.

The Raleigh-based firm adds Compass Advisors and Long Island Wealth Management, bringing seven professionals and combined retirement and wealth advisory capabilities.

Compass said on Tuesday that the FDA recommended a trial showing a survival benefit before the company files a biologics license application for tovecimig in previously treated advanced biliary tract cancer.

Compass Pathways (NASDAQ:CMPS) expects to complete its new drug application submission for COMP360, its investigational psilocybin treatment for treatment-resistant depression, in the fourth quarter, with a potential U.S. launch in the first half of 2027, executives said at the Morgan Stanley Global

Compass Therapeutics, Inc. (NASDAQ:CMPX) shares are trading lower on Tuesday as the FDA feedback raises new questions about the timing and requirements for its tovecimig program. The move is coming even as S&P 500 futures are up 0.1%, pointing to stock-specific pressure rather than a broad risk-off tape. Read Also: Compass Therapeutics' Bile Duct Cancer Drug Seen As New Standard Of Care CMPX Stock Drops After FDA Feedback On Tovecimig BLA Path Compass said the FDA recommended the company run a t

The FDA wants Compass to conduct a trial showing Tovecimig can improve overall survival in patients with previously treated, advanced biliary tract cancer.

A company that generates cash isn’t automatically a winner. Some businesses stockpile cash but fail to reinvest wisely, limiting their ability to expand.

In an interview with BioPharma Dive, Compass executives said that, should the FDA approve their treatment, they hope to capitalize on a strategy pioneered by J&J in selling the ketamine spray Spravato.

Compass (NYSE:COMP) and Midwest Real Estate Data won a federal court ruling over Zillow regarding listing data rules. The decision allows MRED to enforce its data access policies for participants and connected portals. MRED can now move forward with plans for broader national expansion of its listing database. The Compass and MRED court win over Zillow reshapes listing access, but the wider Compass story extends well beyond this case. Our analysis turns up 3 warning signs (2 major) for...

A number of stocks fell in the afternoon session after rising Treasury yields and higher interest rates intensified worries over household finances and discretionary consumption, creating headwind conditions for consumer-facing companies. According to Reuters, as borrowing costs on mortgages, auto loans, and credit cards climb, household budgets are increasingly squeezed, encouraging consumers to prioritize saving and basic necessities over non-essential purchases. In addition, recent economic d

Compass Development Marketing Group’s Helen Howe; David Berg and F. Ron Smith of Compass’ Smith & Berg Property Group; 132 Lake Mary Road in Mammoth Lakes (Compass Development Marketing Group, Smith & Berg, Limelight Residences Mammoth/Christian Pondella) One of Los Angeles County’s fastest-growing teams has been tapped to help sell the remaining units at a Mammoth Lakes branded residential property that’s set new market records and attracted a large contingent of Westside buyers. Compass’ Smith

A federal judge has denied Zillow’s bid to block Midwest Real Estate Data from enforcing its listing rules.

Compass Global will serve as a referral hub and education platform for Compass agents looking to build their cross-border businesses.

Compass, Inc. CEO Robert Reffkin said 42% of U.S. homes on the market saw a price cut in September, the highest share in nearly a decade. Reffkin made the comments in an interview on CNBC’s “Squawk on the Street” on...

Small-cap stocks can be incredibly lucrative investments because their lack of analyst coverage leads to frequent mispricings. However, these businesses (and their stock prices) often stay small because their subscale operations make it harder to expand their competitive moats.

Zillow (ZG) management is broadly constructive amid emerging Preferred market monetization momentum

Compass (COMP) Chief Economist Mike Simonsen joins Josh Lipton on Market Domination to break down the state of US mortgage rates, with the benchmark climbing above 7% to its highest level in more than a year. Simonsen explains what's driving rates higher and how elevated borrowing costs are weighing on potential homebuyers.

The Compass CEO called this the best time in years to be a buyer, armed with a surprisingly compelling statistic. But the two numbers he left out of that CNBC appearance point somewhere else entirely.

Reffkin said the U.S. housing market is increasingly divided by price, with the low-end ‘more mortgage-rate sensitive.’

Compass Pathways (NASDAQ:CMPS) climbed 4% on Wednesday after new 52-week data from the company's Phase III study of COMP360, its investigational oral psilocybin treatment for treatment-resistant depression (TRD). The data, from the open-label Part C portion of Study '005, showed sustained...

Compass said patients who received an additional 25 mg dose of COMP360 saw their depression scores improve by an average of 13 points after 52 weeks.

Compass Pathways plc (NASDAQ:CMPS) reported 52-week topline results from Part C of its Phase 3 COMP005 trial evaluating COMP360, its synthetic psilocybin formulation, in treatment-resistant depression. The open-label portion of the study covered Week 26 through Week 52 and included approximately 70% of the original 258 U.

Compass has said a rolling FDA application is already underway for its COMP360, with the package due to be completed in the fourth quarter of 2026 and a possible U.S. launch in the first half of 2027.

Looking back on consumer discretionary - real estate services stocks’ Q2 earnings, we examine this quarter’s best and worst performers, including Compass (NYSE:COMP) and its peers.

Compass (CMP) is well positioned to outperform the market, as it exhibits above-average growth in financials.

The most closely watched next step for Compass is the completion of its application to the U.S. Food and Drug Administration for COMP360, its synthetic psilocybin treatment aimed at people with depression that has not responded to other options.

Recent commentary on Compass (COMP) has focused on slower sales growth, expense pressures, and negative operating margins. These factors together are shaping a cautious tone around the stock and its near term financial flexibility. See our latest analysis for Compass. At a latest share price of US$11.92, Compass has seen the 1 day share price return fall 6.88% and the 7 day share price return fall 10.71%. The 90 day share price return of 41.90% and 1 year total shareholder return of 40.40%...

Wall Street has set ambitious price targets for the stocks in this article. While this suggests attractive upside potential, it’s important to remain skeptical because analysts face institutional pressures that can sometimes lead to overly optimistic forecasts.

Cosan SA (CSAN) reduces net debt by 20% quarter-over-quarter and cuts G&A expenses by 36% while navigating a transitional period marked by asset sales and management restructuring.

Multi-decade highs in Treasury yields have carved a brutal divide through housing stocks in 2026, and not every real estate name is bleeding. One iBuyer is somehow up 246% while another sits near the bottom of the market.

OPEN's acquisition pace hits about 700 weekly contracts as higher volumes, better conversion and lower marketing spend fuel its turnaround.

Cosan (NYSE:CSAN) reported a narrower net loss for the second quarter of 2026 as the Brazilian conglomerate advanced debt-reduction, divestment and cost-cutting efforts designed to simplify its holding-company structure. Net loss totaled BRL 320 million for the quarter, an improvement from the prio

Compass (CMP) could produce exceptional returns because of its solid growth attributes.

Compass delivered a second quarter marked by robust revenue growth and positive market reaction, with results surpassing Wall Street’s revenue expectations. Management attributed the outperformance to strong transaction volume, especially in luxury markets, and continued outperformance versus the broader real estate market. CEO Robert Reffkin highlighted the impact of high-value transactions in regions like the Bay Area, noting, “This reflects roughly 1,000 basis points of out-performance compar

Compass Pathways (NASDAQ:CMPS) said it remains on track to complete a new drug application for COMP360, its investigational psilocybin treatment for treatment-resistant depression, in the fourth quarter of this year, with a potential U.S. launch expected in the first half of 2027. During Canaccord

OPEN's cost cuts and acquisitions support long-term growth, but housing weakness and capital intensity keep profitability under pressure.

Record EBITDA and synergy realization drive strong results as AI adoption accelerates.

Compass Diversified (NYSE:CODI) reported second-quarter results marked by double-digit growth in subsidiary adjusted EBITDA, improved operating cash flow and lower debt following the sale of Sterno’s food service business, while maintaining its full-year 2026 outlook. GAAP net sales for the second

Compass stock has delivered a very strong 3 year return while the valuation checks now lean toward the shares trading at a premium, which raises questions about how much upside is left from here. Over the last 3 years Compass has returned about 240%, which puts a lot of past share price pressure on the current valuation. Recent earnings momentum and new industry partnerships can support higher expectations, but any shift in housing market conditions or integration setbacks may weigh on what...

NYT's Q2 earnings beat estimates as digital subscriptions, higher ARPU and rising digital ads fueled revenue growth.

Compass (CMP) delivered earnings and revenue surprises of -250.00% and +3.12%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

Compass (COMP) and Revolve Group (RVLV) have more upside compared with MNTN (MNTN) and Opendoor Tech

Compass Pathways (NASDAQ:CMPS) said it remains on track to complete its new drug application, or NDA, filing for COMP360 in treatment-resistant depression in the fourth quarter of 2026, following positive Phase III results and six-month durability data from two trials. Chief Executive Officer Kabir

Compass (COMP) could be a great choice for investors looking to buy stocks that have gained strong momentum recently but are still trading at reasonable prices. It is one of the several stocks that made it through our 'Fast-Paced Momentum at a Bargain' screen.